Kane Biotech (KNE) Q4 2025 earnings summary

Executive summary

• Revenue for 2025 was $427,869, down significantly from $2,080,879 in 2024, mainly due to discontinued animal health contract manufacturing and a strategic shift to the revyve product line.

• Gross profit for 2025 was $(640), impacted by one-time sales and cost of sales adjustments, compared to $872,096 in 2024.

• Net loss from continuing operations for 2025 was $(2,721,239), an improvement from $(3,161,097) in 2024.

• The company undertook significant restructuring in 2025, reducing operating expenses and focusing on commercializing revyve wound care products.

Financial highlights

• Q4 2025 revenue was $(21,140) due to a revenue reversal, compared to $125,859 in Q4 2024.

• Q4 2025 gross profit was $7,567, up from a gross loss of $(87,204) in Q4 2024.

• Q4 2025 net loss was $(546,856), improved from $(1,082,935) in Q4 2024.

• Cash at year-end 2025 was $901,698.

Outlook and guidance

• 2026 objectives include expanding the U.S. and Canadian distributor network, growing revyve sales, and continuing clinical case series.

• Plans to establish a Clinical Advisory Board and resume pre-clinical work on DispersinB Hydrogel for surgical wounds.